<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061940</url>
  </required_header>
  <id_info>
    <org_study_id>SCR-103</org_study_id>
    <nct_id>NCT05061940</nct_id>
  </id_info>
  <brief_title>This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.</brief_title>
  <official_title>Screening Protocol to Assess the Expression of Tumor Associated Antigens (TAAs), Human Papillomavirus (HPV-16) Antigens and Human Leucocyte Antigen (HLA) Sub-Types in Patients With Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repertoire Immune Medicines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repertoire Immune Medicines</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain archived tumor tissue or pre-existing antigen&#xD;
      expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung&#xD;
      Cancers to assess antigen expression and patient suitability for a Repertoire Immune&#xD;
      Medicines Treatment Protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This screening study is intended for men and women at least 18 years of age who have selected&#xD;
      advanced solid tumors. The study will assess the patient's selected tumor antigens and/or&#xD;
      HPV-16 E6/E7 expression profiles. Human leukocyte antigen (HLA) subtype will also be&#xD;
      assessed.&#xD;
&#xD;
      Based on the results, it will be determined if a patient is eligible to be considered for a&#xD;
      Repertoire Immune Medicines sponsored clinical trial(s) testing of the safety and efficacy of&#xD;
      a multi-antigen cytokine-enhanced T cell therapy. No treatment intervention will occur as&#xD;
      part of this screening study.&#xD;
&#xD;
      Upon enrollment, patients will be required to provide archival tumor tissue and saliva&#xD;
      samples. Based upon the results of these diagnostic analyses, if eligible, patients may be&#xD;
      enrolled in an appropriate interventional clinical trial(s) at the discretion of the&#xD;
      Investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of subjects with the expression of multiple tumor associated antigens and/or HPV-16 E6/E7.</measure>
    <time_frame>5 years</time_frame>
    <description>To identify patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancer that could potentially be eligible for Repertoire Immune Medicines clinical trials.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Melanoma</condition>
  <condition>HPV-Related Malignancy</condition>
  <condition>HPV-Related Carcinoma</condition>
  <condition>HPV-Related Cervical Carcinoma</condition>
  <condition>HPV Positive Oropharyngeal Squamous Cell Carcinoma</condition>
  <condition>Lung Cancer, Nonsmall Cell</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tumor Profiling</intervention_name>
    <description>Testing TAA and HPV expression. HLA typing.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE Slides&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for inclusion in this study must meet all of the following criteria:&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to provide written informed consent&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Histologically- or cytologically-confirmed, relapsed/refractory, and metastatic or&#xD;
             locally advanced head and neck, cervical, melanoma or non-small cell lung cancers.&#xD;
             Other solid tumor types may be analyzed at the discretion of the Sponsor&#xD;
&#xD;
          -  Able to provide archived tumor tissue or have existing data on TAAs, HPV status or HLA&#xD;
             sub-type&#xD;
&#xD;
          -  Willing to provide a saliva sample&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There are no exclusion criteria for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ted Reiss, MD, MBE</last_name>
    <role>Study Director</role>
    <affiliation>Repertoire Immune Medicines</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marlyane Motta, BS</last_name>
    <phone>7865641228</phone>
    <email>mmotta@repertoire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela House, RN</last_name>
      <phone>480-323-1364</phone>
      <email>clinicaltrials@honorhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Joyce Schaffer, RN</last_name>
      <phone>480-323-1364</phone>
      <email>clinicaltrials@honorhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Moser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Michigan Hotline</last_name>
      <phone>800-865-1125</phone>
      <email>CancerAnswerLine@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Swiecicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle McCreary</last_name>
      <email>Danielle.Mccreary@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV-16 E6/E7</keyword>
  <keyword>TT-101</keyword>
  <keyword>PRIME-102</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

